Virtual Library

Start Your Search

Eray Karahacioglu



Author of

  • +

    EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.16-07 - National, Observational, Multicentric Study in Stage III Non-Small Cell Lung Cancer Patients in Turkey: Stone Trial (Now Available) (ID 2570)

      08:00 - 18:00  |  Author(s): Eray Karahacioglu

      • Abstract
      • Slides

      Background

      In this national, non-interventional study, our aim is to collect stage III non-small cell lung cancer (NSCLC) data derived from medical records in nationwide to capture and consolidate information of treatment patterns, treatment effectiveness and patient outcomes in the real-world setting. This study was carried out with the collaboration of Turkish Society for Radiation Oncology.

      Method

      Patients newly diagnosed with primary stage III NSCLC between 01 January 2013 and 31 December 2017 included. A total of 556 patients from 10 hospitals in Turkey were included in this study. Patient characteristics, initial treatment modalities, chemotherapy regimens, overall (OS) and local progression free survival (LPFS), failure patterns and secondary treatments after recurrence for recurrent patients were analyzed.

      Result

      Median age was 63 years (range, 56-69 years). 488 patients (%87.8) were male and 68 patients (%12.2) were female. Histopathological type was adenocarcinoma in 197 patients (%35.4), squamous cell carcinoma in 291 patients (%52.3) and others (Large Cell Carcinoma, mixed and unknown) in 68 patients (%12.3). 385 patients (%69.2) received definitive/curative therapy, 23 patients (%4.1) received palliative, 33 patients (%5.9) received adjuvant and 63 patients (%11.3) received neoadjuvant oncological treatment. 54.8% of patients received concomitant chemoradiotherapy, 22.1% of patients received concomitant chemoradiotherapy+ adjuvant chemotherapy, 12.2% of patients received only radiotherapy and, 10.8% of patients received sequential chemotherapy followed by radiotherapy. 75 patients (13.4%) underwent curative resection as primary treatment and, 33 (5.9%) of them received adjuvant chemoradiotherapy and/or radiotherapy. The 2- and 3-year of OS were 57%, and %43, respectively. 2- and 3-year of PFS were %38 and %25, respectively.

      Conclusion

      To our best knowledge, this is the first national study representing valuable information about real-life data in stage III NSCLC population in Turkey.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.